News Headlines

  1. Charles River Extends Commitment To Advanced Therapy Developers With Second Incubator Program Cohort 12/11/2025

    Charles River Laboratories International, Inc. today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to extensive scientific and commercial expertise, as well as a comprehensive ecosystem of discovery, development, and manufacturing capabilities, to expedite the development of technologies and life-changing therapies for patients in need.

  2. Tivic Acquires Ready-To-Scale cGMP Manufacturing And Development Assets To Accelerate Commercialization Of Entolimod; Tivic Growth Backed By $90M+ Financing Package 12/11/2025

    Tivic Health Systems, Inc., a diversified therapeutics company, today announced it has acquired the strategic manufacturing and development assets of Scorpius Holdings, Inc. and is launching Velocity Bioworks, a wholly owned subsidiary of Tivic, to provide contract development and manufacturing services to Tivic and other companies.

  3. Lonza's Cocoon Platform Receives Advanced Manufacturing Technologies (AMT) Designation From The U.S. FDA 12/11/2025

    Lonza today announced that the Cocoon Platform has been granted AMT Designation by the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research.

  4. Polpharma Biologics And Libbs Farmacêutica Sign Licensing Agreement For A Biosimilar For Autoimmune Diseases 12/10/2025

    Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market.

  5. Bora Pharmaceuticals And Corealis Pharma Forge Strategic Alliance To Deliver Seamless, End-To-End Oral Solid Dose Development 12/9/2025

    Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a global leader in pharmaceutical manufacturing, and Corealis Pharma Inc., a leading early-phase Contract Development Manufacturing Organization (CDMO), have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and manufacturing. The collaboration will simplify the drug development process and provide a more scalable pathway to commercialization via a single continuum.

  6. Lilly To Build $6B Facility To Manufacture Active Pharmaceutical Ingredients In Alabama 12/9/2025

    Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the third of four new U.S. sites Lilly plans to announce, will produce small molecule synthetic and peptide medicines.

  7. Fosun Pharma's Subsidiary Yao Pharma And Pfizer Enter Into Exclusive Collaboration And License Agreement 12/9/2025

    Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement.

  8. uBriGene Biosciences And Circurna Announce Strategic Partnership To Accelerate Development And Manufacturing Of Circular RNA/LNP Therapeutics 12/9/2025

    uBriGene Biosciences, a global CDMO specializing in Advanced Therapy Medicinal Product (ATMP) GMP development and manufacturing, today announced a strategic partnership with Circurna, a biotechnology company pioneering next-generation circular RNA (circRNA) therapeutics.

  9. Akadeum Life Sciences Announces Establishment Of The Akadeum CDMO Alliance Program 12/9/2025

    Akadeum Life Sciences, the leader in buoyant cell separation, announces the establishment of the Akadeum CDMO Alliance™ and the first two members in the consortium.

  10. Grace and Molecule.one To Transform Peptide Building Block Synthesis With AI And Automation 12/8/2025

    The two companies enter into a multi-year strategic agreement to accelerate drug development timelines, strengthen U.S. manufacturing capabilities and help bring lifesaving medicines to patients faster.